



ISAKOS  
CONGRESS  
2025



MUNICH  
GERMANY  
June 8-11

# Blood Flow Signals Through the Bone Cortex on Ultrasonography as a Screening Test for Detecting Bone Marrow Lesions on Magnetic Resonance Imaging in Patients with Early Knee Osteoarthritis

Naoki Takemoto, MD

Department of Orthopedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Japan



# Faculty Disclosure Information

- Nothing to disclosure




ISAKOS  
CONGRESS  
2025



**MUNICH**  
**GERMANY**  
June 8–11

# Introduction

## Blood flow signals (BFS) through the bone cortex on ultrasonography (US)



**BFS have been observed in patients with knee osteoarthritis (OA)**  
**and are thought to indicate the presence of bone lesions**


## Bone marrow lesions (BML) on magnetic resonance imaging (MRI)



### Fluid-sensitive MRI (STIR, T2 FS)

- Indistinct high-signal regions
- Adjacent to the articular cartilage
- Absence of clear fracture lines
- Exclusion of trauma, rheumatoid arthritis, and tumor

**BML are characteristic imaging findings of knee OA. BMLs have been reported to reflect high metabolic activity of the bones and microfractures.**




BFSs through the bone cortex and BMLs can be used to assess bone lesions. However, no studies have reported their correlation.

This study aimed to assess whether BFS through the bone cortex on US can be used as a screening test to detect BML on MRI in patients with early knee OA.

## Patient selection

- Nonrandomized, prospective, multicenter clinical trial
- Patients with knee joint pain who were diagnosed with early knee OA based on **the Luyten diagnostic criteria**
- We enrolled **107 patients** who underwent MRI and confirmed the presence or absence of BFS through the bone cortex on US


## Detecting BFS through the bone cortex on US




- In the supine position with slight knee flexion
- In power or color Doppler mode on US

## Detecting BML on MRI

- **WORMS (Whole-Organ Magnetic Resonance Imaging Score)**



Sag 3 compartments  
× Cor 5 compartments  
= **15** compartments



0	none
1	< 25%
2	25% ~ 50%
3	> 50%

- BML score was calculated for each area.
- Areas with a total score of  $\geq 1$  were defined as having BML.

# Results

**107 cases**

**Male: 42, Female: 65, mean age: 67.4 years**

## Femur

### BML

BFS		+	-	Total
	+	24	2	26
	-	5	76	81
	Total	29	78	107

$$\chi^2(1) = 73.9, p < 0.001$$

Sensitivity	83 %	PPV	92 %
Specificity	97 %	NPV	94 %

## Tibia

### BML

BFS		+	-	Total
	+	28	4	32
	-	4	71	75
	Total	32	75	107

$$\chi^2(1) = 72.2, p < 0.001$$

Sensitivity	83 %	PPV	92 %
Specificity	97 %	NPV	94 %

※ PPV: Positive Predictive Value, NPV: Negative Predictive Value

**BFS through the bone cortex on US can be used as a screening test to detect BML on MRI in patients with early knee OA.**

# References

1. Langworthy M, et al. Knee osteoarthritis: disease burden, available treatments, and emerging options. *Ther Adv Musculoskelet Dis*. 2024; 15:16.
2. Madry H, et al. The basic science of the subchondral bone. *Knee Surg Sports Traumatol Arthrosc*. 2010;18:419–33.
3. Luyten FP, et al. Toward classification criteria for early osteoarthritis of the knee. *Semin Arthritis Rheum*. 2018;47:457–63.
4. Ota S, et al. Symptomatic bone marrow lesions induced by reduced bone mineral density in middle-aged women: a cross-sectional Japanese population study. *Arthritis Res Ther*. 2019;21:113.
5. Roemer FW, et al. Evaluating the structural effects of intra-articular sprifermin on cartilage and non-cartilaginous tissue alterations, based on sqMRI assessment over 2 years. *Osteoarthritis Cartilage*. 2020;28:1229-1234.
6. Waish DA, et al. Osteoarthritis Bone Marrow Lesions. *Osteoarthritis Cartilage*. 2023;31:11-17.
7. Roemer FW, et al. Change in MRI-detected subchondral bone marrow lesions is associated with cartilage loss: the MOST Study. A longitudinal multicentre study of knee osteoarthritis. *Osteoarthritis Cartilage* 2009;68:1461-1465.
8. Haugen IK, et al. A need for new imaging modality to detect inflammation in rheumatoid arthritis and osteoarthritis? *Ann Rheum Dis*. 2016;75:479–80.
9. Seefried L, et al. Efficacy of zoledronic acid in the treatment of nonmalignant painful bone marrow lesions: A triple-blind, randomized, placebo-controlled Phase III clinical trial (ZoMARS). *J Bone Miner Res*. 2022;37:420–27.
10. Peterfy CG, et al. Whole-Organ magnetic resonance imaging Score (WORMS) of the knee in osteoarthritis. *Osteoarthr Cartil*. 2004;12:177–90.
11. Iwasaki T, et al. Clinical characteristic of knee osteoarthritis with doppler ultrasonography at the medial epicondyle of the femur (in Japanese). *Clin Orthop Surg*. 2022;57:177–81.